stoxline Quote Chart Rank Option Currency Glossary
  
2seventy bio, Inc. (TSVT)
2.65  -0.09 (-3.28%)    02-06 10:37
Open: 2.72
High: 2.74
Volume: 48,963
  
Pre. Close: 2.74
Low: 2.62
Market Cap: 137(M)
Technical analysis
2025-02-06 10:21:21 AM
Short term     
Mid term     
Targets 6-month :  3.28 1-year :  3.62
Resists First :  2.81 Second :  3.1
Pivot price 2.57
Supports First :  2.34 Second :  1.95
MAs MA(5) :  2.67 MA(20) :  2.55
MA(100) :  3.82 MA(250) :  4.32
MACD MACD :  -0.1 Signal :  -0.2
%K %D K(14,3) :  74.4 D(3) :  69.1
RSI RSI(14): 47.5
52-week High :  6.4 Low :  2.34
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ TSVT ] has closed below upper band by 22.0%. Bollinger Bands are 61.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.84 - 2.85 2.85 - 2.86
Low: 2.68 - 2.69 2.69 - 2.7
Close: 2.72 - 2.74 2.74 - 2.76
Company Description

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Headline News

Thu, 06 Feb 2025
Abecma Sales Hit $242M: 2seventy bio's Path to Profitability Takes Shape - StockTitan

Mon, 20 Jan 2025
2seventy bio, Inc. (NASDAQ:TSVT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Sun, 19 Jan 2025
Barclays PLC Has $380,000 Position in 2seventy bio, Inc. (NASDAQ:TSVT) - MarketBeat

Tue, 31 Dec 2024
2seventy bio, Inc.'s (NASDAQ:TSVT) 28% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St

Fri, 15 Nov 2024
Analysts Have Been Trimming Their 2seventy bio, Inc. (NASDAQ:TSVT) Price Target After Its Latest Report - Simply Wall St

Thu, 14 Nov 2024
2seventy bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 52 (M)
Shares Float 50 (M)
Held by Insiders 4.2 (%)
Held by Institutions 90.5 (%)
Shares Short 5,080 (K)
Shares Short P.Month 4,680 (K)
Stock Financials
EPS -1.84
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.55
Profit Margin -207.3 %
Operating Margin -99.3 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 12.5 %
Gross Profit (p.s.) -1.76
Sales Per Share 0.88
EBITDA (p.s.) -2.61
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -1.47
PEG Ratio 0
Price to Book value 0.58
Price to Sales 3.03
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android